When did Adaptive Biotechnologies report Q4 2024 earnings?

Adaptive Biotechnologies (ADPT) reported Q4 2024 earnings on February 11, 2025 after market close.

What were Adaptive Biotechnologies's Q4 2024 revenue and EPS?

Adaptive Biotechnologies reported revenue of $47.5M and eps of $-0.23 for Q4 2024.

Did Adaptive Biotechnologies beat estimates in Q4 2024?

Revenue beat the consensus estimate of $46.0M by $1.4M. EPS beat the consensus estimate of $-0.27 by $0.04.

Where can I find Adaptive Biotechnologies's Q4 2024 SEC filings?

You can read the 10-K periodic report (0000950170-25-030913) directly on SEC EDGAR. The filing index links above go to sec.gov.

Adaptive Biotechnologies ADPT Q4 2024 Annual earnings

Reported February 11, 2025 · After market close

Revenue$47.5MBeat by $1.4M

EPS-$0.23Beat by $0.04

Revenue estimate$46.0M

EPS estimate-$0.27

Next report

Date not yet announced

Financials

Q4 2024

Income statement

See full

Revenue$47.5M+3.7%

Gross profit$29.4M+12.4%

Operating income-$33.8M+52.4%

Net income-$33.7M+51.5%

EPS (diluted)-$0.22+54.2%

Balance sheet

See full

Cash & equivalents$47.9M-26.3%

Total debt$222.7M-2.9%

Total equity$202.7M-34.3%

Total assets$539.4M-18.4%

Cash flow

See full

Operating cash flow-$12.5M+53.6%

CapEx$80.0K-93.8%

Free cash flow-$12.6M+55.5%

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$884.74M+24.7%

Enterprise value$1.06B+21.3%

P/S4.9×+0.8×

Profitability

See full

Gross margin59.7%+4.1pp

Operating margin-90.8%-22.0pp

Net margin-89.1%-21.9pp

FCF margin-55.3%-16.8pp

Returns & leverage

See full

Return on equity-62.4%+4.7pp

Debt / equity1.1×+0.4×

Current ratio2.9×-1.8×

Segments

By product

See full

Service$40.1M+30.5%

Service And Licensing Revenue$5.0M-20.0%

Collaboration Revenue$3.5M-55.8%

Regulatory Milestone Revenue-—

By segment

See full

Mrd Business$40.1M+30.5%

Immune Medicine Business$7.3M-51.3%

Versus estimates

Revenue

Q1 2026$70.9MBeat by $9.9M Q4 2025$71.7MBeat by $10.8M Q3 2025$94.0MBeat by $34.6M Q2 2025$58.9MBeat by $3.5M Q1 2025$52.4MBeat by $10.3M

Q4 2024$47.5MBeat by $1.4M

Diluted EPS

Q1 2026-$0.13Beat by $0.03 Q4 2025-$0.09Beat by $0.10 Q3 2025-$0.15Beat by $0.01 Q2 2025-$0.17Beat by $0.07 Q1 2025-$0.20Beat by $0.08

Q4 2024-$0.23Beat by $0.04

Ask the moment Adaptive Biotechnologies reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Adaptive Biotechnologies report Q4 2024 earnings?: Adaptive Biotechnologies (ADPT) reported Q4 2024 earnings on February 11, 2025 after market close.
What were Adaptive Biotechnologies's Q4 2024 revenue and EPS?: Adaptive Biotechnologies reported revenue of $47.5M and eps of $-0.23 for Q4 2024.
Did Adaptive Biotechnologies beat estimates in Q4 2024?: Revenue beat the consensus estimate of $46.0M by $1.4M. EPS beat the consensus estimate of $-0.27 by $0.04.
Where can I find Adaptive Biotechnologies's Q4 2024 SEC filings?: You can read the 10-K periodic report (0000950170-25-030913) directly on SEC EDGAR. The filing index links above go to sec.gov.